GlassScriptPhysician profile
Sara M Ray
NPI 1750846986
$1,930.07
in general payments reported to CMS, 2019-2025
32 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $795 · 2023: $613 · 2024: $211 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.63 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $198.95 | 2022 | |
| Janssen Biotech, INC. | $193.81 | 2021-2025 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $131.61 | 2023-2024 | |
| Sobi, INC | $131.17 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $99.99 | 2022-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $88.33 | 2022-2025 | Jemperli, Zejula, Blenrep |
| Amgen INC. | $87.87 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Astrazeneca Pharmaceuticals LP | $87.36 | 2022-2025 | Calquence |
| Sanofi-Aventis U.S. LLC | $84.95 | 2022 | |
| Merck Sharp & Dohme LLC | $74.40 | 2022-2023 | Keytruda |
| Genentech USA, INC. | $70.99 | 2023-2024 | Venclexta, Polivy, Lunsumio |
| Pfizer INC. | $66.36 | 2022-2024 | |
| Gilead Sciences, INC. | $63.95 | 2022-2024 | Trodelvy |
| Daiichi Sankyo INC. | $56.86 | 2021-2024 | Enhertu, Injectafer |
| Array Biopharma INC | $53.55 | 2022-2024 | Lorbrena, Mektovi, Braftovi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $51.59 | 2023 | Krazati |
| Eisai INC. | $36.93 | 2022-2023 | |
| Lilly USA, LLC | $36.48 | 2022-2023 | Verzenio, Jaypirca |
| Genzyme Corporation | $35.53 | 2022-2025 | |
| Puma Biotechnology, INC. | $33.81 | 2021 | |
| Taiho Oncology, INC. | $33.22 | 2023 | |
| Beigene USA, INC. | $27.33 | 2024 | Brukinsa |
| Stemline Therapeutics INC. | $24.68 | 2023 | Orserdu |
| Exelixis INC. | $24.05 | 2022 | |
| Karyopharm Therapeutics INC. | $21.77 | 2023 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $21.50 | 2022 | |
| Emd Serono, INC. | $20.00 | 2025 | |
| Abbvie INC. | $17.25 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $16.56 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.55 | 2023 | Givlaari |
| Heron Therapeutics, INC. | $13.08 | 2021 | |
| Blueprint Medicines Corporation | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.